More than three years after its creation, Stramsen Biotech, Inc. has become one of the world's leading startups in the field of plant-based biotechnology. According to Stonebridge Advisory, a third-party valuation company based in Los Angeles, California, after an initial valuation in 2023, it was officially valued at $6.5 billion. This is stated in media reports.
The assessment was made after a thorough and lengthy analysis of its management team, board of directors, team of scientists, assets, debt indicators, commercial value of Stramsen products, as well as total revenues or financial forecast of the company, etc. Stramsen Biotech is one of the largest companies in the world. There are 33 candidate drugs in the Stramsen portfolio. The company has access to more than 8,000 medicinal plants that will be used for future drug discoveries.
Private negotiations on a possible reverse merger are ongoing between Stramsen Biotech Inc. and several American public companies. Stramsen hopes to acquire one of the companies as part of a reverse merger deal. The management of Stramsen hopes that Stramsen will most likely soon become a public company through a reverse merger. The announcement will be made after the parties agree to the terms of the reverse merger deal.
Stramsen Biotech's goal is to capture between 1% and 5% of the $1.7 trillion market over the next 5-15 years. The company's annual gross revenue is expected to range from $17 billion to $85 billion in the next 10-15 years.
